Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
Market Cap | 441.814 Million | Shares Outstanding | 75.011 Million | Avg 30-day Volume | 1.548 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.09 |
Price to Revenue | 5.1642 | Debt to Equity | 3.2906 | EBITDA | -270.714 Million |
Price to Book Value | 10.0218 | Operating Margin | -136.9637 | Enterprise Value | 1.059 Billion |
Current Ratio | 3.994 | EPS Growth | -0.235 | Quick Ratio | 3.771 |
1 Yr BETA | 1.084 | 52-week High/Low | 23.18 / 5.25 | Profit Margin | -136.0029 |
Operating Cash Flow Growth | -181.3193 | Free Cash Flow to Firm (FCFF) TTM | -239.649 Million | Free Cash Flow to Equity (FCFE) TTM | -216.728 Million |
Altman Z-Score | -1.5427 | ||||
Earnings Report | 2024-02-22 |
Please sign in first
none
3.1 Thousand total shares from 1 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HEERMA PETER CHIEF COMMERCIAL OFFICER |
|
80,257 | 2023-10-03 | 3 |
CLINE CHRISTOPHER R. CHIEF FINANCIAL OFFICER |
|
50,574 | 2023-09-05 | 5 |
REED ELIZABETH E SVP, GC & CORPORATE SECRETARY |
|
58,096 | 2023-08-31 | 4 |
ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D |
|
61,173 | 2023-08-31 | 4 |
DUBE ERIC M CHIEF EXECUTIVE OFFICER |
|
242,595 | 2023-08-31 | 4 |
|
44,500 | 2023-05-17 | 1 | |
|
12,750 | 2023-05-17 | 1 | |
|
42,500 | 2023-05-17 | 1 | |
|
22,375 | 2023-05-17 | 1 | |
|
22,375 | 2023-05-17 | 1 | |
|
74,500 | 2023-05-17 | 1 | |
|
15,750 | 2023-05-17 | 1 | |
|
17,000 | 2023-05-17 | 1 | |
|
24,500 | 2023-05-17 | 1 | |
CALVIN SANDRA SVP, CHIEF ACCOUNTING OFFICER |
|
42,247 | 2023-05-10 | 3 |
INRIG JULA CHIEF MEDICAL OFFICER |
|
37,757 | 2023-01-31 | 2 |
|
146,919 | 2022-05-11 | 0 | |
CLAGUE LAURA CHIEF FINANCIAL OFFICER |
|
35,655 | 2022-05-10 | 0 |
ROSENBERG NOAH L. CHIEF MEDICAL OFFICER |
|
47,614 | 2021-08-13 | 0 |
MCFARLANE NEIL F. CHIEF OPERATING OFFICER |
|
26,988 | 2019-05-15 | 0 |
|
29,000 | 2019-05-08 | 0 | |
SHIH ALVIN EVP OF RESEARCH & DEVELOPMENT |
|
158,334 | 2016-09-01 | 0 |
|
29,000 | 2016-05-18 | 0 | |
VALEUR JENSEN MARGARET E GENERAL COUNSEL |
|
100,000 | 2016-02-01 | 0 |
|
2,658,854 | 2015-01-13 | 0 | |
PLOTKIN HORACIO CHIEF MEDICAL OFFICER |
|
91,767 | 2014-12-12 | 0 |
|
129,165 | 2014-11-21 | 0 | |
|
No longer subject to file | 2014-11-14 | 0 | |
|
51,665 | 2014-08-14 | 0 | |
PANOFF MARC L CHIEF FINANCIAL OFFICER |
|
221,100 | 2014-02-24 | 0 |
|
2,097,671 | 2013-12-24 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-10-04 16:05:09 -0400 | 2023-10-03 | S | 3,091 | $8.25 | d | 80,257 | direct | -3.7975 | -12.0253 | -23.9241 | 0.0 | 1 | -31.1392 | 26 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
TRAVERE THERAPEUTICS INC TVTX | 2023-11-28 12:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 22:15:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 21:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 21:15:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 20:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 20:15:05 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 19:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 19:15:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 18:45:05 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 18:15:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 17:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 17:15:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 16:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 16:15:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 15:45:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 15:15:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 14:45:03 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 14:15:04 UTC | 5.07 | 0.25 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 13:45:04 UTC | 4.8598 | 0.4602 | 1900000 |
TRAVERE THERAPEUTICS INC TVTX | 2023-11-27 13:15:04 UTC | 4.8598 | 0.4602 | 1900000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund | TVTX | -10028.0 shares, $-143199.84 | 2023-08-31 | N-PORT |
LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio | TVTX | -31.0 shares, $-277.14 | 2023-09-30 | N-PORT |
JNL Series Trust- JNL Multi-Manager Alternative Fund | TVTX | -23486.0 shares, $-209964.84 | 2023-09-30 | N-PORT |